PHILADELPHIA, Aug. 23, 2011 /PRNewswire/ — ERT, a global
technology-driven provider of clinical services and customizable
medical devices to biopharmaceutical and healthcare organizations,
announced today the appointment of Linda Deal to lead ERT’s Health
Outcomes Research initiatives. This strategic appointment
extends ERT’s commitment to health outcomes research and augments
its Patient Reported Outcomes capabilities and multi modality
product offering with deeper scientific expertise.
Jeffrey Litwin MD, President and CEO of ERT comments, “Linda’s
expertise and extensive industry knowledge will assist us in
increasingly providing innovative outcomes research solutions to
better serve our clients’ developing needs. Having worked inside
sponsor organizations and across a number of entities within the
PRO community, Linda brings insight and perspective on the creation
and implementation of Patient, Clinician and Observer reported
outcomes. Her domain knowledge will enable her to add
considerable value to ERT’s offerings and to our clients.”
Ms Deal brings a breadth of experience in health outcomes and in
the development and validation of patient reported assessments.
Most recently she was the Immunology Patient Reported
Outcomes (PRO) Lead at Janssen Pharma, a division of Johnson &
Johnson, where she was responsible for developing and integrating
the PRO strategy within the end to end development process. Prior
to Johnson & Johnson, Linda was head of the PRO Center in
Global Health Outcomes Assessment (GHOA) at Wyeth Research, now
Pfizer. She has also supported health economics and outcomes
research for Wyeth, Research Triangle Institute, and Glaxo
Welcome.
Over her career, she has designed a number of assessments used
in clinical trials today and has prepared over 20 regulatory
briefing documents addressing PRO development and validation for
supporting registration and labeling. She n
‘/>”/>
